{"id":"https://openalex.org/W2020485499","doi":"https://doi.org/10.1016/j.ejps.2004.11.011","title":"Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method","display_name":"Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method","publication_year":2005,"publication_date":"2005-01-25","ids":{"openalex":"https://openalex.org/W2020485499","doi":"https://doi.org/10.1016/j.ejps.2004.11.011","mag":"2020485499","pmid":"https://pubmed.ncbi.nlm.nih.gov/15734300"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejps.2004.11.011","doi":"https://doi.org/10.1016/j.ejps.2004.11.011","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejps.2004.11.011","pdf_url":null,"source":{"id":"https://openalex.org/S119477091","display_name":"European Journal of Pharmaceutical Sciences","issn_l":"0928-0987","issn":["0928-0987","1879-0720"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-3","ki-jl-2","medline","norway-2","oarl","poland-100","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutical Sciences","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078166589","display_name":"Alex Avdeef","orcid":"https://orcid.org/0000-0002-3139-5442","observed_orcids":["https://orcid.org/0000-0002-3139-5442"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Alex Avdeef","raw_affiliation_strings":["pION Inc., 5 Constitution Way, Woburn, MA 01801, USA. aavdeef@pion-inc.com","pION Inc., 5 Constitution Way, Woburn, MA 01801, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"pION Inc., 5 Constitution Way, Woburn, MA 01801, USA. aavdeef@pion-inc.com","institution_ids":[]},{"raw_affiliation_string":"pION Inc., 5 Constitution Way, Woburn, MA 01801, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079220895","display_name":"Per Artursson","orcid":"https://orcid.org/0000-0002-3708-7395","observed_orcids":["https://orcid.org/0000-0002-3708-7395"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Per Artursson","raw_affiliation_strings":["Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060323901","display_name":"Sibylle Neuhoff","orcid":"https://orcid.org/0000-0001-8809-1960","observed_orcids":["https://orcid.org/0000-0001-8809-1960"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]},{"id":"https://openalex.org/I4210143795","display_name":"AstraZeneca (Sweden)","ror":"https://ror.org/04wwrrg31","country_code":"SE","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210143795"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Sibylle Neuhoff","raw_affiliation_strings":["AstraZeneca, DMPK and Bioanalytical Chemistry, SE-421 83 M\u00f6lndal, Sweden","Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, DMPK and Bioanalytical Chemistry, SE-421 83 M\u00f6lndal, Sweden","institution_ids":["https://openalex.org/I4210143795"]},{"raw_affiliation_string":"Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058442775","display_name":"Lucia Lazorova","orcid":"https://orcid.org/0009-0001-8993-3784","observed_orcids":["https://orcid.org/0009-0001-8993-3784"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Lucia Lazorova","raw_affiliation_strings":["Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053696627","display_name":"Johan Gr\u00e5sj\u00f6","orcid":"https://orcid.org/0000-0002-0080-3714","observed_orcids":["https://orcid.org/0000-0002-0080-3714"]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Johan Gr\u00e5sj\u00f6","raw_affiliation_strings":["Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031735609","display_name":"Staffan Tavelin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123387679","display_name":"Uppsala University","ror":"https://ror.org/048a87296","country_code":"SE","type":"education","lineage":["https://openalex.org/I123387679"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Staffan Tavelin","raw_affiliation_strings":["Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Division of Pharmaceutics, Uppsala University, Box 580, SE-751 23 Uppsala, Sweden","institution_ids":["https://openalex.org/I123387679"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5078166589"],"corresponding_institution_ids":[],"apc_list":{"value":3070,"currency":"USD","value_usd":3070},"apc_paid":null,"fwci":5.727,"has_fulltext":false,"cited_by_count":216,"citation_normalized_percentile":{"value":0.96972485,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"24","issue":"4","first_page":"333","last_page":"349"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.5375999808311462,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.5375999808311462,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.28049999475479126,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.06629999727010727,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/caco-2-permeability","display_name":"Caco-2 permeability","score":0.8360000252723694},{"id":"https://openalex.org/keywords/ph-dependent-permeability","display_name":"pH-dependent permeability","score":0.875},{"id":"https://openalex.org/keywords/cationic-drugs","display_name":"cationic drugs","score":0.9559999704360962},{"id":"https://openalex.org/keywords/weakly-basic-drugs","display_name":"weakly basic drugs","score":0.8999999761581421},{"id":"https://openalex.org/keywords/verapamil","display_name":"verapamil","score":0.9160000085830688},{"id":"https://openalex.org/keywords/propranolol","display_name":"propranolol","score":1.0},{"id":"https://openalex.org/keywords/intrinsic-permeability","display_name":"intrinsic permeability","score":0.7590000033378601},{"id":"https://openalex.org/keywords/permeability-prediction-model","display_name":"permeability prediction model","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5249754786491394},{"id":"https://openalex.org/C143050476","wikidata":"https://www.wikidata.org/wiki/Q194502","display_name":"Sink (geography)","level":2,"score":0.4513855576515198},{"id":"https://openalex.org/C120882062","wikidata":"https://www.wikidata.org/wiki/Q28352","display_name":"Permeability (electromagnetism)","level":3,"score":0.42739182710647583},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.33757877349853516},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3274475336074829},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.14743730425834656},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11648896336555481},{"id":"https://openalex.org/C205649164","wikidata":"https://www.wikidata.org/wiki/Q1071","display_name":"Geography","level":0,"score":0.052276939153671265},{"id":"https://openalex.org/C41625074","wikidata":"https://www.wikidata.org/wiki/Q176088","display_name":"Membrane","level":2,"score":0.04358479380607605},{"id":"https://openalex.org/C58640448","wikidata":"https://www.wikidata.org/wiki/Q42515","display_name":"Cartography","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004364","descriptor_name":"Pharmaceutical Preparations","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006863","descriptor_name":"Hydrogen-Ion Concentration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010539","descriptor_name":"Permeability","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018938","descriptor_name":"Caco-2 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejps.2004.11.011","doi":"https://doi.org/10.1016/j.ejps.2004.11.011","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ejps.2004.11.011","pdf_url":null,"source":{"id":"https://openalex.org/S119477091","display_name":"European Journal of Pharmaceutical Sciences","issn_l":"0928-0987","issn":["0928-0987","1879-0720"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-d","doyens","jufo-3","ki-jl-2","medline","norway-2","oarl","poland-100","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmaceutical Sciences","raw_type":"journal-article"},{"id":"pmid:15734300","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15734300","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.6240000128746033,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":57,"referenced_works":["https://openalex.org/W54789453","https://openalex.org/W164073564","https://openalex.org/W174314275","https://openalex.org/W258716081","https://openalex.org/W424609096","https://openalex.org/W1520727604","https://openalex.org/W1542164875","https://openalex.org/W1563591576","https://openalex.org/W1596837460","https://openalex.org/W1597285101","https://openalex.org/W1604977289","https://openalex.org/W1844834026","https://openalex.org/W1937048566","https://openalex.org/W1957898861","https://openalex.org/W1977698867","https://openalex.org/W1983111851","https://openalex.org/W1983777266","https://openalex.org/W1991979573","https://openalex.org/W1992885480","https://openalex.org/W2001626903","https://openalex.org/W2014259987","https://openalex.org/W2014467650","https://openalex.org/W2015201186","https://openalex.org/W2018206163","https://openalex.org/W2032865438","https://openalex.org/W2038344991","https://openalex.org/W2040930785","https://openalex.org/W2040969251","https://openalex.org/W2043096887","https://openalex.org/W2046697069","https://openalex.org/W2046827775","https://openalex.org/W2065602354","https://openalex.org/W2067953813","https://openalex.org/W2072184780","https://openalex.org/W2073101936","https://openalex.org/W2073661241","https://openalex.org/W2076899651","https://openalex.org/W2083330758","https://openalex.org/W2083715780","https://openalex.org/W2092815169","https://openalex.org/W2105493745","https://openalex.org/W2112893277","https://openalex.org/W2132542476","https://openalex.org/W2145812143","https://openalex.org/W2158793749","https://openalex.org/W2163602402","https://openalex.org/W2187984788","https://openalex.org/W2264001376","https://openalex.org/W2283221217","https://openalex.org/W2285524653","https://openalex.org/W2426277199","https://openalex.org/W2485283686","https://openalex.org/W2499551151","https://openalex.org/W4300720636","https://openalex.org/W6687153498","https://openalex.org/W6693213899","https://openalex.org/W6815670826"],"related_works":["https://openalex.org/W2083330758","https://openalex.org/W2076899651","https://openalex.org/W1997381364","https://openalex.org/W2055724461","https://openalex.org/W2071464010","https://openalex.org/W4407853869","https://openalex.org/W1994818884","https://openalex.org/W2034695997","https://openalex.org/W177887527","https://openalex.org/W2890344407"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":11},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":16}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}